Department of Neurology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
Neurochem Res. 2017 Dec;42(12):3362-3371. doi: 10.1007/s11064-017-2382-x. Epub 2017 Aug 21.
Lewy bodies and Lewy neurites in the brain constitute the main histopathological features of Parkinson's disease (PD) and dementia with Lewy bodies. They comprise amyloid-like fibrils composed of α-synuclein (αS), a small protein (~14 kDa). Because the aggregation of αS in the brain has been implicated as a critical step in the development of these diseases, the research for disease-modifying drugs has focused on modification of the αS aggregation process in the brain. Recent studies using synthetic αS peptides, a cell culture model, transgenic mice models, and human samples such as cerebrospinal fluids and the blood of PD patients have suggested that pre-fibrillar forms of αS (i.e., oligomers) are more critical than fibrillar forms (such as Lewy bodies) in the pathogenesis of α-synucleinopathies. Based on the accumulating evidence that oligomers play a central role in the pathogenesis of PD and other α-synucleinopathies (the "oligomer hypothesis"). This report reviews the recent findings regarding the oligomer hypothesis in the research of α-synucleinopathies.
路易体和路易神经纤维是帕金森病(PD)和路易体痴呆的主要组织病理学特征。它们由α-突触核蛋白(αS)组成,αS 是一种小蛋白(约 14 kDa)。由于脑内 αS 的聚集被认为是这些疾病发展的关键步骤,因此,疾病修饰药物的研究重点是改变脑内的 αS 聚集过程。最近的研究使用合成的 αS 肽、细胞培养模型、转基因小鼠模型以及 PD 患者的脑脊液和血液等人类样本,提示 αS 的预纤维形式(即寡聚物)比纤维形式(如路易体)在 α-突触核蛋白病的发病机制中更为关键。基于寡聚物在 PD 和其他 α-突触核蛋白病发病机制中起核心作用的累积证据(“寡聚物假说”)。本报告综述了近年来关于 α-突触核蛋白病中寡聚物假说的研究结果。